Compare Abbott Laboratories (ABT) vs Newmont Corporation (NEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Newmont Corporation — how do they compare? Abbott Laboratories trades at $110.73 (market cap $187.95B), while Newmont Corporation trades at $118.2 (market cap $123.50B). The key difference: Abbott Laboratories is the larger of the two by market cap, and Abbott Laboratories pays the higher dividend (2.32%). Which is the better fit depends on your goals.
| ABT | NEM | |
|---|---|---|
Market Cap | $187.95B | $123.50B |
Sector | Health | Basic Materials |
52-Week High | $136.62 | $131.95 |
52-Week Low | $82.57 | $67.38 |
Enterprise Value | $214.96B | $120.09B |
Dividend Yield | 2.32% | 0.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
Newmont Corporation (NEM) trades at $119.12, up 1.59% with strong technical momentum as it approaches resistance near $120. The company demonstrates robust fundamentals with Q2 2026 EPS beating expectations at $2.10 versus $2.05 forecast, continuing a trend of earnings outperformance. Revenue growth accelerated to $22.67 billion in 2025 with net income margin expanding to 33.36%. Recent news highlights resolution of Nevada disputes with Barrick Mining and strong gold price environment supporting miner profitability.
Outlook remains positive with analyst consensus price target of $133 representing 11.6% upside potential. Key opportunities include continued gold price strength and operational efficiency gains, while risks involve potential cost inflation and gold price volatility. With 76% analyst buy ratings and improving cash flow trends, NEM appears well-positioned for continued growth in the current commodity cycle.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →
